Am J Transplant, Volume 18, Suppl 3 Archives - Page 165 of 211 - ATC Abstracts

2018 American Transplant Congress
MeltDose Prolonged-Release Once-Daily Tacrolimus (LCPT) vs. Conventional Tacrolimus Formulations in the Initial Maintenance of De Novo Kideny Transplant Recipients across Europe: STEADY Study
K. Budde,¹ G. Piotti,² C. Procaccianti,³ G. Nicolini,³ S. Geraci,³ D. Surace.³
¹Charité Universitatsmedizin, Berlin, Germany; ²Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; ³Chiesi Farmaceutici S.p.A., Parma, Italy.
Tacrolimus is an immunosuppressant drug available as a twice-daily formulation (Prograf®, IR-Tac), or as once-daily formulations (Advagraf®, PR-Tac; Envarsus®, LCPT). LCPT has shown clinical non-inferiority…
2018 American Transplant Congress
Impact of Steroid Maintenance on the Outcomes of HLA-DR Mismatch Kidney Transplantation
B. Chopra, K. Sureshkumar.
Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch poses high immunologic risk and is associated with inferior outcomes. We aimed to explore the impact of enhanced immunosuppression…
2018 American Transplant Congress
Can We Optimise Immunosuppression Strategies in Our Older Renal Transplant Recipients?
M. Morton,¹ K. Parker,¹ C. Morecroft.²
¹Manchester University Foundation Trust, Manchester, United Kingdom; ²Liverpool John Moores University, Liverpool, United Kingdom.
Renal transplantation provides a survival advantage for patients including those with multiple co-morbidities and older age compared to remaining on dialysis. The optimal immunosuppressive regime…
2018 American Transplant Congress
Opting out and Offers of 'Alibis' for Potential Living Kidney Donors in the US
R. Iskander,¹ S. Kulkarni,² C. Thiessen.²
¹McMaster University, Hamilton, ON, Canada; ²Yale University School of Medicine, New Haven, CT.
Purpose: To delineate rates of and reasons for opting out of living kidney donation, to determine if and how transplant centers offer alibis, to assess…
2018 American Transplant Congress
Chronic Changes on Time Zero Living Donor Allograft Biopsy Portraits Worse Donor Renal Function
A. Nishio-Lucar,¹ J. Murphy,² A. Sites,³ H. Cathro,² A. Doyle,¹ K. Warburton,¹ A. Agarwal.⁴
¹Medicine, University of Virginia, Charlottesville, VA; ²Pathology, University of Virginia, Charlottesville, VA; ³Transplant Services, University of Virginia, Charlottesville, VA; ⁴Surgery, University of Virginia, Charlottesville, VA.
The prognostic ability of zero hour biopsy (ZHB) in renal allografts has not been fully elucidated. ZHB utility predicting living kidney donor (LKD) renal recovery…
2018 American Transplant Congress
Risk Factors for Failure to Complete Post-Donation Follow-Up among Obese Living Kidney Donors
R. Reed,¹ P. MacLennan,¹ B. Shelton,¹ M. Mustian,¹ D. McWilliams,¹ D. Sawinski,² J. Locke.¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL; ²Medicine, University of Pennsylvania, Philadelphia, PA.
Introduction: Living kidney donors in the United States who were obese at the time of donation are at greater risk of end-stage renal disease than…
2018 American Transplant Congress
Prediction of 90 Days Readmission after Kidney Transplantation Including Natural Language Processing
X. Zhang,¹ M. Arenson,⁴ J. Kim,⁴ G. Karadkhele,¹ J. Hogan,^1,5 Y. Zhang,⁶ A. Adams,¹ R. Patzer.^1,2,3
¹Department of Surgery, Emory University, Atlanta; ²Department of Epidemiology, Emory University, Atlanta; ³Emory Transplant Center, Emory Healthcare, Atlanta; ⁴School of Medicine, Emory University, Atlanta; ⁵Department of Pediatrics, Emory University, Atlanta; ⁶Rollins School of Public Health, Emory University, Atlanta.
Early identification of hospital readmission for End Stage Renal Disease (ESRD) patients who obtained kidney transplantation potentially help decrease their risk of readmission after transplantation,…
2018 American Transplant Congress
Induction Therapy with Low-Dose Rituximab Could Be a Risk Factor of BKV Associated Nephropathy in Kidney Transplant Recipients
R. Murakami,¹ D. Nagawa,¹ M. Nakata,¹ I. Narita,¹ T. Fujita,¹ M. Shimada,¹ N. Nakamura,¹ H. Tomita,¹ S. Hatakeyama,² T. Yoneyama,² Y. Hashimoto,² T. Koie,² C. Ohyama.²
¹Nephrology, Hirosaki University, Hirosaki, Japan; ²Urology, Hirosaki University, Hirosaki, Japan.
Background.In kidney transplant recipients, BK polyoma virus (BKV) infection is common and serious complication that could lead to graft loss. Previous studies reported that 30-40%…
2018 American Transplant Congress
Conversion to Mizoribine with Mycophenolate Eliminates or Reduces the BK Virus Load in Kidney Transplant Recipients: A Prospective Study
X-.P. Yuan, C-.B. Chen, Y. Zheng, J. Zhou, C. Wang, X. He.
Organ Transplant Center, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: BK virus (BKV) allograft nephropathy (BKVAN) is a graft-threatening complication after kidney transplantation. Current consensus regarding the prevention of BKVAN is to screen for…
2018 American Transplant Congress
Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis
R. Deng, B. Huang, Y. Shi, Y. Ma.
Organ Transplantation Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Background: A prolonged-release formulation of tacrolimus has been developed to provide once-daily dosing, with similar efficacy and safety to the standard twice-daily dosing and it…